Hospitals achieved up to 98% decrease in MRSA superbug infection rates and $1.9 million in savings with programs using Nozin® Nasal Sanitizer® antiseptic on patients.
Across the U.S., hundreds of hospitals are utilizing Nozin® Nasal Sanitizer® antiseptic to improve patient care and reduce healthcare costs. Five major hospitals presented clinical evidence of lower costs and reduced methicillin-resistant Staphylococcus aureus (MRSA) healthcare-associated infections (HAIs) after introducing Nozin® Nasal Sanitizer® programs. The results were presented at APIC 2019 conference in Philadelphia and IDWeek 2019 annual conference in Washington, D. C.
The hospitals' improved outcomes included lower MRSA infection rates, decrease in patient isolation days and reduced use of contact precautions contributed to an estimated $1.9 million in savings for the facilities.
The video below looks at the clinical results with Nozin programs in their hospitals.
For more information on the hospital clinical studies go here.
Editor's note: this article was originally posted on Nozin's website.
Results reported at Association of Professionals in Infection Control (APIC) and Infectious Disease Society of America (IDSA IDWeek) annual conferences.